Christian Agboton
0000-0002-1178-2429
Takeda Pharmaceutical Company
31 papers found
Refreshing results…
P325 Integrating efficacy and safety of vedolizumab and other advanced therapies for the treatment of ulcerative colitis: Results from a network meta-analysis
P374 Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial
P039 Integrating Maintenance Efficacy and Safety of Vedolizumab and Other Advanced Therapies for the Treatment of Ulcerative Colitis: A Network Meta-Analysis
P038 Comparing the Efficacy and Safety of Subcutaneous Vedolizumab Versus Adalimumab for the Treatment of Ulcerative Colitis: A Network Meta-Analysis
Pgi39 - Darvadstrocel in the Management of Complex Perianal Fistulas: The Role of Patient Registry Data Collection to Support Performance-Based Risk Sharing Agreements
Sa1724 - Expanded Allogeneic Adipose Derived Mesenchymal Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Crohn's Disease Has Rapid Onset of Clinical Remission and Low Relapse Rate by Week 52
Sa1756 - Patient-Reported Improvements in Pain and Discharge on the Perianal Disease Activity Index Correlate with Objective Assessments of Perianal Fistula Remission in Patients with Crohn's Disease
P594 Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)
P691 Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52
AB0314 Awareness and Acceptance of Biosimilars by Rheumatologists in Eleven Eu Countries
P484. Access to biologics and biosimilars across 11 European Union countries
Missing publications? Search for publications with a matching author name.